April 25, 2023 07:37 AM EDT

Novartis pays German biotech $40M for radioligand therapy, diagnostic hitting 'first-in-class' target

Amber Tong

Novartis’ decision to buy a radioligand therapy from Clovis is proving a boon for 3B Pharmaceuticals, the small German biotech that originally developed the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis pays German biotech $40M for radioligand therapy, diagnostic hitting 'first-in-class' target

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

No­var­tis pays Ger­man biotech $40M for ra­di­oli­gand ther­a­py, di­ag­nos­tic hit­ting 'first-in-class' tar­get

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Novartis pays German biotech $40M for radioligand therapy, diagnostic hitting 'first-in-class' target

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial